Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR3A | P46098 | 1/20 | 0.51 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.42 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.42 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18291382 | 0.92 | CYP2D6 (0.44) | — | |
| SCHEMBL20037855 | 0.90 | CYP2D6 (0.50) | HTR3A | |
| SCHEMBL12975623 | 0.89 | HTR2C (0.47) | DDB1CRBN | |
| SCHEMBL254836 | 0.85 | CHRNB2 (0.42) | — | |
| SCHEMBL2636373 | 0.82 | HTR3A (0.48) | HTR3A | |
| SCHEMBL28772971 | 0.80 | DDB1 (0.49) | HTR3ADDB1CRBN | |
| SCHEMBL18929477 | 0.80 | KDM4E (0.51) | — | |
| SCHEMBL12093737 | 0.80 | KDM4E (0.47) | — | |
| SCHEMBL22608995 | 0.79 | HTR3A (0.51) | HTR3ADDB1CRBN | |
| SCHEMBL31412742 | 0.79 | HTR3A (0.61) | HTR3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022174253-A1 | HPK1 ANTAGONISTS AND USES THEREOF | Nimbus Saturn, Inc. (US) | 2022-08-18 | — | — | WO | disclosed |
| WO-2018109202-A1 | MONOCYCLIC OGA INHIBITOR COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2018-06-21 | — | — | WO | disclosed |
| US-9163012-B2 | Carbamate and urea inhibitors of 11β-hydroxysteroid dehydrogenase 1 | VITAE PHARMACEUTICALS, INC. (US) | 2015-10-20 | — | — | US | disclosed |
| EP-2051980-B1 | PYRROLOTRIAZINE KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2014-02-26 | — | — | EP | disclosed |
| EP-2438043-A1 | CARBAMATE AND UREA INHIBITORS OF 11BETA-HYDROXYSTEROID DEHYDROGENASE 1 | Vitae Pharmaceuticals, Inc. (US) | 2012-04-11 | — | — | EP | disclosed |
| US-20110053943-A1 | CARBAMATE AND UREA INHIBITORS OF 11ß-HYDROXYSTEROID DEHYDROGENASE 1 | VITAE PHARMACEUTICALS, INC. | 2011-03-03 | — | — | US | disclosed |
| WO-2010141424-A1 | CARBAMATE AND UREA INHIBITORS OF 11BETA-HYDROXYSTEROID DEHYDROGENASE 1 | VITAE PHARMACEUTICALS, INC. (US) | 2010-12-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110053943-A1 | CARBAMATE AND UREA INHIBITORS OF 11ß-HYDROXYSTEROID DEHYDROGENASE 1 | HSD11B1, HSD11B2, HSD3B1 | HTR3A 3365/4885DDB1 537/4885CRBN 1207/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.